Appendix Table C129. Clinical renal outcomes (outcomes part C), AL monotherapy versus control treatment trials

| **Study** | **End Stage Renal Disease, n/N (%)** | | **Doubling of Serum Creatinine, n/N (%)** | | **Halving of GFR, n/N (%)** | | **Progression from Micro- to Macroalbuminuria, n/N (%)** | | **Composite Renal Outcome, n/N (%)\*\*** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **AL** | **Control** | **AL** | **Control** | **AL** | **Control** | **AL** | **Control** | **AL** | **Control** |
| ***HMG-CoA reductase inhibitors versus placebo trials (n=11)*** | | | | | | | | | | |
| Kendrick, 201087  AFCAPS/TexCAPS |  |  |  |  |  |  |  |  |  |  |
| Ridker, 201088  JUPITER |  |  |  |  |  |  |  |  |  |  |
| Nakamura, 200989  MEGA |  |  |  |  |  |  |  |  |  |  |
| Colhoun, 200990  CARDS |  |  |  |  |  |  |  |  |  |  |
| Koren, 200991  ALLIANCE |  |  |  |  |  |  |  |  |  |  |
| Rahman, 200893  ALLHAT | 32/779 (4.1) | 31/778 (4.0) |  |  |  |  |  |  | (B)50/779 (6.4) | (B)52/778 (6.7) |
| Chonchol, 200794  4S |  |  |  |  |  |  |  |  |  |  |
| Kjekshus, 200796  CORONA |  |  |  |  |  |  |  |  |  |  |
| Lemos, 200597  LIPS |  |  |  |  |  |  |  |  |  |  |
| Asselbergs, 20042  PREVD |  |  |  |  |  |  |  |  |  |  |
| Tonelli, 200498  WOSCOPS/CARE/ LIPID |  |  |  |  |  |  |  |  |  |  |
| Tonelli, 200399  CARE |  |  |  |  |  |  |  |  |  |  |

Appendix Table C129. Clinical renal outcomes (outcomes part C), AL monotherapy versus control treatment trials (continued)

| **Study** | **End Stage Renal Disease, n/N (%)** | | **Doubling of Serum Creatinine, n/N (%)** | | **Halving of GFR, n/N (%)** | | **Progression from Micro- to Macroalbuminuria, n/N (%)** | | **Composite Renal Outcome, n/N (%)\*\*** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***High versus low dose HMG-CoA reductase inhibitor trials (n=1)*** | | | | | | | | | | |
|  | **High Dose** | **Low Dose** | **High Dose** | **Low Dose** | **High Dose** | **Low Dose** | **High Dose** | **Low Dose** | **High Dose** | **Low Dose** |
| SEARCH, 2010100 |  |  |  |  |  |  |  |  |  |  |
| Shepherd, 2008101  TNT |  |  |  |  |  |  |  |  |  |  |
| ***HMG-CoA Reductase Inhibitor versus Bile Acid Sequestrant trials (n=1)*** | | | | | | | | | | |
| Tonolo, 2006104 |  |  |  |  |  | \*†(4) | †(15) |  |  |  |
| ***Gemfibrozil versus placebo/control trials (n=2)*** | | | | | | | | | | |
| Tonelli, 200498  VA-HIT | 0/199 | 0/200 |  |  |  |  |  |  |  |  |
| Samuelsson, 199784 | 2/28 (7.1) | 1/29 (3.4) |  |  |  |  |  |  |  |  |

AL = antilipid; GFR = glomerular filtration rate;   
\* p < 0.05 versus control  
\*\*See Composite renal outcome definitions table  
†Study reported that conversion from microalbuminuria to overt proteinuria occurred in 4 vs. 15% in simvastatin vs. cholestyramine subjects, respectively (p<0.01). However, from results reported, it was not possible to determine the numerator and denominator used to derive these results for both treatment groups.